Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos V Rizos

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Expert Opinion on Pharmacotherapy|April 5, 2014
Antihypertensive drug therapy in patients with African ancestryChristos V Rizos, Moses S Elisaf
European Journal of Pharmacology|March 19, 2013
Metformin and cancerChristos V Rizos, Moses S Elisaf
World Journal of Cardiology|July 29, 2014
Antihypertensive drugs and glucose metabolismChristos V Rizos, Moses S Elisaf
Current Medical Research and Opinion|July 24, 2014
Reaching low density lipoprotein cholesterol targetsChristos V Rizos, Fotios Barkas, Moses S Elisaf
Archives of Toxicology|May 12, 2016
The current role of thiazolidinediones in diabetes managementChristos V Rizos, Anastazia Kei, Moses S Elisaf
World Journal of Nephrology|January 20, 2017
Severe hyperkalemia following blood transfusions: Is there a link?Christos V Rizos, Haralampos J Milionis, Moses S Elisaf
Expert Opinion on Drug Metabolism & Toxicology|December 16, 2017
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetesChristos V Rizos, Theodosios D Filippatos, Moses S Elisaf
Drug Safety|May 3, 2014
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseasesMichael S Kostapanos, Christos V Rizos, Moses S Elisaf
Journal of Cardiovascular Pharmacology and Therapeutics|March 27, 2019
Emerging Fixed-Dose Combination Treatments for HyperlipidemiaEleni Pappa, Christos V Rizos, Theodosios D Filippatos, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|August 23, 2017
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid VariablesTheodosios D Filippatos, Anastazia Kei, Christos V Rizos, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Expert Opinion on Pharmacotherapy|April 5, 2014
Antihypertensive drug therapy in patients with African ancestryChristos V Rizos, Moses S Elisaf
European Journal of Pharmacology|March 19, 2013
Metformin and cancerChristos V Rizos, Moses S Elisaf
World Journal of Cardiology|July 29, 2014
Antihypertensive drugs and glucose metabolismChristos V Rizos, Moses S Elisaf
Current Medical Research and Opinion|July 24, 2014
Reaching low density lipoprotein cholesterol targetsChristos V Rizos, Fotios Barkas, Moses S Elisaf
Archives of Toxicology|May 12, 2016
The current role of thiazolidinediones in diabetes managementChristos V Rizos, Anastazia Kei, Moses S Elisaf
World Journal of Nephrology|January 20, 2017
Severe hyperkalemia following blood transfusions: Is there a link?Christos V Rizos, Haralampos J Milionis, Moses S Elisaf
Expert Opinion on Drug Metabolism & Toxicology|December 16, 2017
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetesChristos V Rizos, Theodosios D Filippatos, Moses S Elisaf
Drug Safety|May 3, 2014
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseasesMichael S Kostapanos, Christos V Rizos, Moses S Elisaf
Journal of Cardiovascular Pharmacology and Therapeutics|March 27, 2019
Emerging Fixed-Dose Combination Treatments for HyperlipidemiaEleni Pappa, Christos V Rizos, Theodosios D Filippatos, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|August 23, 2017
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid VariablesTheodosios D Filippatos, Anastazia Kei, Christos V Rizos, et al.
Pageof 4